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Abstract
For elderly patients with locally advanced esophageal cancer, therapeutic approaches
and outcomes in a modern cohort are not well characterized. Patients ≥70 years
old with clinical stage II and III esophageal cancer diagnosed between 1998 and
2012 were identified from the National Cancer Database and stratified based on
treatment type. Variables associated with treatment utilization were evaluated using
logistic regression and survival evaluated using Cox proportional hazards analysis.
Propensity matching (1:1) was performed to help account for selection bias. A
total of 21,593 patients were identified. Median and maximum ages were 77 and
90, respectively. Treatment included palliative therapy (24.3%), chemoradiation
(37.1%), trimodality therapy (10.0%), esophagectomy alone (5.6%), or no therapy
(12.9%). Age ≥80 (OR 0.73), female gender (OR 0.81), Charlson–Deyo comorbidity
score ≥2 (OR 0.82), and high-volume centers (OR 0.83) were associated with a
decreased likelihood of palliative therapy versus no treatment. Age ≥80 (OR 0.79)
and Clinical Stage III (OR 0.33) were associated with a decreased likelihood, while
adenocarcinoma histology (OR 1.33) and nonacademic cancer centers (OR 3.9),
an increased likelihood of esophagectomy alone compared to definitive chemoradiation. Age ≥80 (OR 0.15), female gender (OR 0.80), and non-Caucasian race
(OR 0.63) were associated with a decreased likelihood, while adenocarcinoma histology (OR 2.10) and high-volume centers (OR 2.34), an increased likelihood of
trimodality therapy compared to definitive chemoradiation. Each treatment type
demonstrated improved survival compared to no therapy: palliative treatment (HR
0.49) to trimodality therapy (HR 0.25) with significance between all groups. Any
therapy, including palliative care, was associated with improved survival; however,
subsets of elderly patients with locally advanced esophageal cancer are less likely
to receive aggressive therapy. Care should be taken to not unnecessarily deprive
these individuals of treatment that may improve survival.

Introduction
Esophageal cancer comprises a significant portion of gastrointestinal malignancies with an annual incidence of
approximately 17,000 in the United States and over 450,000
worldwide [1, 2]. Despite improvements in outcome over
time, annual death rates continue to nearly match annual
2886

incidence and prognosis remains poor with an overall
survival of around 20% at 5 years for locoregional disease
[1, 2]. Surgical resection has been a key component of
definitive therapy; however, its utilization is often tempered
by potential morbidity and mortality associated with
esophagectomy [3–5]. For surgically fit patients, a standard
of care for locally advanced disease is trimodality therapy
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with neoadjuvant concurrent chemoradiation followed by
esophagectomy based on improved outcomes compared
to surgery alone [6, 7].
When aggressive combined-modality therapy is a standard treatment approach as it is for esophageal cancer,
the elderly patient in particular presents a therapeutic
challenge. The decision whether to offer definitive therapy,
or any therapy at all, is determined in the context of an
increased risk of toxicity and a more limited life expectancy. Studies examining patterns or outcomes of treatment
for esophageal cancer in this population are limited, and
most are small, single-institution experiences. In this setting, esophagectomy in the elderly is less utilized and
associated with a potential increase in postoperative complications, but is feasible in selected patients with acceptable outcomes [5, 8–10]. Definitive chemoradiation is also
more infrequently considered in the elderly, yet treatment
appears to be well tolerated with efficacy comparable to
younger patients [11–14]. Population-based analyses have
elucidated some broad trends and outcomes in this older
population and these largely mirror the single-institution
studies [15, 16]. However, these studies predate the definitive treatment paradigm shift to neoadjuvant therapy and
thus may be less applicable to a modern cohort of elderly
patients.
To address current trends and predictors of treatment
utilization and associated outcomes, we queried the
National Cancer Database (NCDB). A joint program of
the Commission on Cancer of the American College of
Surgeons and the American Cancer Society, the NCDB

compiles data from over 1500 commission-accredited cancer programs and captures about 70% of newly diagnosed
patients with cancer in the United States annually. Here,
we examine elderly patients (≥70 years old) with locally
advanced esophageal cancer to evaluate how this population is being managed in the modern era and what factors
influence specific treatment choices. Modalities evaluated
were no treatment delivered, palliative therapies, definitive
chemoradiation, esophagectomy alone, and trimodality,
with the primary aim to compare overall survival between
these groups. Secondary aims included identifying variables
independently associated with receiving each modality.

Material and Methods
Patients
The NCDB Participant User File for esophageal cancer
was used to identify clinical stage II and III patients
≥70 years old diagnosed between 1998 and 2012. As patients
and centers are deidentified by the NCDB, this study was
deemed exempt by the Washington University School of
Medicine Institutional Review Board.
Using the NCDB data dictionary, patient characteristics
were dichotomized into: Caucasian or non-Caucasian; population type of metropolitan, urban, or rural; average income
<$38,000 or ≥$38,000 by zip code; education level of ≥21%
or <21% in zip code with no high school diploma; and
insurance status of Medicare, Medicaid, private, or other
government (e.g., Federal insurance or Tricare). Using

Figure 1. Consort diagram.
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ICD-
0-
3 codes, histology subtypes were dichotomized as
either adenocarcinoma or squamous cell of the
esophagus.
Patients were excluded from analysis if they had unknown
clinical stage, discordant clinical stage (recorded clinical
T/N stage did not match recorded overall clinical stage),
metastatic disease, or received endoscopic or ablative
therapy. A Consolidated Standards of Reporting Trials
(CONSORT) diagram is shown in Figure 1. An interquartile
range of center volume by the number of years a center
contributed to the NCDB was calculated. Centers in the
top quartile were labeled “high-volume” centers, all others
were labeled “low-volume” centers. Patients were considered
to have received concurrent chemoradiation if the date
from diagnosis to initiation of systemic therapy and the
date from diagnosis to initiation of radiation therapy were
within a 14-
day limit. If these dates were separated by
>14 days, they were considered to have received sequential
therapy. For the purposes of this analysis, palliative therapy
was defined as any treatment not considered definitive
therapy for curative intent for locally advanced disease
and included: chemotherapy only, radiation therapy only,
or sequential chemotherapy/radiation therapy. Trimodality
therapy was defined as receipt of neoadjuvant chemoradiation therapy followed by esophagectomy.

Statistical analysis
Descriptive statistics of continuous variables were expressed
as mean ± standard error of the mean. Univariate comparisons included independent sample t-tests to compare
normally distributed continuous variables and chi-square
analysis for comparisons of categorical data. Stepwise
backwards logistic regression was used to identify variables
independently associated with receiving palliative therapy
(relative to no treatment) and trimodality therapy (relative
to definitive chemoradiation) as this method allows for
more robust analysis to determine significance in a large
cohort. Criteria for entry into the logistic regression model
included a P value of <0.05 on univariate analysis. Kaplan–
Meier analysis was performed to compare median overall
survival outcomes by therapy type (including no treatment), with log-rank testing. A Cox proportional hazards
model was created to identify variables independently
associated with increased risk of overall mortality.
To assist in controlling for patient and tumor factors
potentially involved in selection bias, two propensity-
matched analyses were performed: (1) matching no treatment patients to those receiving palliative treatment, (2)
matching definitive chemoradiation patients to those
receiving trimodality therapy, (3) matching definitive
chemoradiation patients to those receiving esophagectomy
alone. Patients were matched on the following variables:
2888
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age (as a continuous variable, to better account for possible unmeasured age-
related comorbidities), sex, race,
distance from treatment center, center type, center volume,
insurance type, income, education level, population type,
Charlson-Deyo score, histology type, clinical stage, T stage,
tumor grade, and tumor location. After propensity score
calculation using logistic regression, patients were matched
1:1 using nearest neighbor matching with a caliper distance
of 0.20 of the standard deviation of the logit of the propensity score. Postmatching diagnostics included analysis
of the standardized mean differences between the matching
variables. For both matched analyses performed, no interactions demonstrated a standardized mean difference >0.20.
Kaplan–Meier analysis was again performed among these
matched pairs with log-rank testing.
P values <0.05 were considered statistically significant.
Statistical analyses were performed in SPSS 23.0 for
Windows (SPSS Inc, Chicago IL, 2013).

Results
Patient characteristics
A total of 21,593 patients with locally advanced esophageal
cancer age ≥70 were analyzed (Table 1). The median age
was 77 and patients were predominantly Caucasian (89.0%),
male (72.0%), and of a higher educational (82.1%) and
income (79.9%) status. There was a near-even split between
clinical stage II (52.6%) and stage III (47.4%) patients.
The majority of tumors were located in the lower third
of the esophagus (56.7%) and were of adenocarcinoma
histology (52.1%).

Treatment utilization and outcome
Among the treatment categories analyzed, definitive (concurrent) chemoradiation was the most common (37.1%)
followed by palliative therapy (24.3%). In the definitive
chemoradiation group, the mean elapsed time of radiation
treatment was 42.0 ± 0.3 days and most (70.6%) received
multiagent chemotherapy. Within the palliative therapy
group, the majority received radiation alone (50.7%), followed by sequential chemoradiation (34.1%) and chemotherapy alone (15.2%). Ten percent received trimodality
therapy. For the neoadjuvant portion, mean elapsed time
of radiation treatment was 39.0 ± 0.8 days with 80.1%
receiving multiagent chemotherapy. Trends in utilization
of each over time are shown in Figure S1. Between 1998
and 2012, as compared to prior years, trimodality use
steadily increased, while esophagectomy alone increased
in early years, but declined significantly after 2009. Between
age groups within the elderly cohort, there was heterogeneity in treatment utilization as well (Table 2). Notably,

© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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Table 1. Demographics and clinical characteristics for elderly clinical
stage II and III esophageal cancer patients from the NCDB diagnosed
between 1998 and 2012.
Demographic or clinical characteristic

Patients (N = 21,593)

Age at diagnosis, years (median)
Sex
Male
Female
Race
Caucasian
Non-Caucasian
Charlson/Deyo comorbidity score
0
1
≥2
Missing
Income (by zip code)
<$38,000
≥$38,000
Education (by zip code)
≥21% with no high school diploma
<21% with no high school diploma
Metropolitan population type
Distance from treatment center, miles
(median)
Center volume (cases/year)
Top quartile
2nd quartile
3rd quartile
Bottom quartile
Clinical stage
II
III
Histology
Adenocarcinoma
Squamous cell carcinoma
Unknown
Tumor location
Cervical esophagus
Upper third
Middle third
Lower third
Unknown
Treatment type
No treatment
Palliative therapy
Concurrent chemoradiation
Esophagectomy alone
Trimodality therapy
Unknown

77 (70–90)
15,544 (72.0%)
6049 (28.0%)
19,227 (89.0%)
2366 (11.0%)
11,413 (52.9%)
3440 (15.9%)
1119 (5.2%)
5621 (26.0%)
4348 (20.1%)
17,245 (79.9%)
3874 (17.9%)
17,719 (82.1%)
16,991 (78.7%)
8.7 (0–3691)

3.4–18.9
1.84–3.3
1.08–1.83
0.20–1.07
11,351 (52.6%)
10,242 (47.4%)
11,249 (52.1%)
9068 (42.0%)
1276 (5.9%)
724 (3.4%)
1303 (6.0%)
3545 (16.4%)
12,239 (56.7%)
3782 (17.5%)
2787 (12.9%)
5252 (24.3%)
8010 (37.1%)
1215 (5.6%)
2159 (10.0%)
2170 (10.1%)

patients aged 80 and older were significantly more likely
to receive palliative therapy or no treatment and less likely
to receive trimodality therapy or surgery alone.
Overall survival by treatment type is shown in Figure 2.
Patients who underwent trimodality therapy had the most
favorable outcome with a median survival of 26.8 months
(95% CI: 24.9–28.7) followed by esophagectomy alone at

© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

19.3 months (95% CI: 17.1–21.5) and chemoradiation at
14.0 months (95% CI: 13.5–14.5). Median survival for palliative therapy was 9.7 months (95% CI: 9.3–10.1). Those
who did not undergo any tumor-
directed therapy had a
median survival of 3.6 months (95% CI: 3.4–3.9). When
separated by histology, survival trends by treatment type
were generally comparable to the overall cohort with squamous cell carcinoma patients often trending toward worse
survival than their adenocarcinoma counterparts (Fig. 3). As
with the full cohort, the most favorable outcomes were seen
with trimodality with median survival for squamous cell
carcinoma of 24.8 months (95% CI: 19.7–30.0) and for
adenocarcinoma of 27.7 months (95% CI: 25.5–30.0), and
the least favorable outcomes were with no treatment with
median survivals of 2.9 months (95% CI: 2.6–3.2) and
4.6 months (95% CI: 4.1–5.1), respectively. Interestingly, for
squamous cell carcinoma only, median survival for esophagectomy alone (15.9 months, 95% CI: 12.3–19.5), though slightly
higher than 14.3 months for concurrent chemoradiation, was
not statistically significant (P = 0.44). Otherwise, median
survivals were statistically different for the remaining treatment comparisons for squamous cell carcinoma and all
treatment comparisons for adenocarcinoma (P < 0.001).

Predictors of utilization – palliative therapy
versus no treatment
On univariate analysis, the palliative therapy group was
younger (age 70–79, 57.9% vs. 49.7%), more likely to be
male (67.9% vs. 64.2%) and clinical stage II (52.0% vs.
45.9%), and lived closer to their treatment center (24.9
vs. 31.7 miles) (Table S1). On multivariate logistic regression, age ≥ 80 (OR 0.73), female gender (OR 0.81), Charlson-
Deyo comorbidity score ≥1 (OR 0.82–0.85), clinical stage
III (OR 0.80), and receiving treatment at a high-
volume
center (OR 0.83) were independently associated with a
decreased likelihood of receiving palliative therapy (Table 3).
Only higher levels of education (OR 1.25) or insurance
status including private insurance (OR 1.55) and Medicare
(OR 1.77) were independently associated with receiving
palliative therapy. After propensity matching (1105 patient
pairs), there was a significant improvement in median survival from 3.5 months (95% CI: 3.1–3.9) in the no treatment group to 9.9 months (95% CI: 9.1–10.6) in the
palliative therapy group, P < 0.001 (Figs. S2 and S3).

Predictors of utilization – trimodality
therapy versus definitive chemoradiation
On univariate analysis, the trimodality group was overwhelmingly younger (age 70–79, 93.3% vs. 68.8%) and
more likely to be male (83.5% vs. 73.0%), Caucasian
(95.9% vs. 90.0%), and treated at a high-volume center
2889
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Table 2. Distribution of treatments by age group.
Treatment type

No treatment
Palliative therapy
Concurrent
chemoradiation
Esophagectomy
alone
Trimodality
therapy
Unknown

Age at diagnosis (years)
70–79
(n = 14,580)

≥80
(n = 7013)

1386 (9.5%)
3041 (20.9%)
5528 (37.9%)

1401 (20.0%)
2211 (31.5%)
2482 (35.4%)

912 (6.2%)

303 (4.3%)

2014 (13.8%)

145 (2.1%)

1699 (11.7%)

471 (6.7%)

P value

<0.001

(40.7% vs. 22.0%). Trimodality was more often associated
with adenocarcinoma histology (72.6% vs. 51.3%) and
tumors in the lower third of the esophagus (77.8% vs.
56.7%) (Table S2). Multivariate analysis confirmed that
patients who were ≥80 years old (OR 0.15), female (OR
0.80), or non-Caucasian (OR 0.63) were significantly less
likely to receive trimodality, while those with adenocarcinoma histology (OR 2.10) or treated at a high-volume
center (OR 2.34) were more likely to receive trimodality
(Table 3). After propensity matching (955 patient pairs),
there was a significant improvement in median survival
from 15.6 months (95% CI: 14.3–16.9) in the concurrent
chemoradiation group to 27.6 months (95% CI: 24.7–30.4)
among trimodality patients, P < 0.001 (Figs. S4 and S5).
Because age was a strong predictor of not receiving
trimodality therapy, we then explored perioperative morbidity and mortality between age groups. We found that

mean length of hospital stay (12.8 vs. 14.3 days, P = 0.25)
and 30-day readmission rates (6.7% vs. 7.0%, P = 0.90)
were not significantly different. On the other hand, 30-
day and 90-day mortality were worse for patients ≥80 years
old (10.4% vs. 5.5%, P = 0.03, and 23.7% vs. 14.2%,
P = 0.006, respectively), though the number of these older
patients is small (n = 145) relative to the entire cohort
(Table S3).

Predictors of utilization – esophagectomy
alone versus definitive chemoradiation
While its use appears to have declined in recent years
and trimodality is the more common surgical approach
for definitive therapy in our cohort, esophagectomy alone
is still utilized as definitive therapy in a portion of patients.
Therefore, we also compared patients receiving esophagectomy alone to those receiving concurrent chemoradiation
in the definitive setting. On univariate analysis, the
esophagectomy group was younger (age 70–79, 75.1% vs.
69.0%), more likely to be male (77.4% vs. 72.3%), Caucasian
(95.4% vs. 89.9%), and live farther from the treatment
center (54.2 vs. 32.7 miles). As with trimodality, esophagectomy alone was also more often associated with adenocarcinoma histology (71.5% vs. 52.4%) and tumors in
the lower third of the esophagus (81.6% vs. 68.8%) (Table
S4). On multivariate logistic regression, age ≥80 (OR 0.79),
clinical stage III (OR 0.33), and tumors in the upper and
middle third of the esophagus (OR 0.31–0.69) were independently associated with a decreased likelihood, while
those with a Charlson-
Deyo comorbidity score ≥1 (OR
1.31–1.47), adenocarcinoma histology (OR 1.33), and being

Figure 2. Kaplan–Meier overall survival for elderly patients with locally advanced esophageal cancer stratified by type of treatment.
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A Squamous cell carcinoma

B Adenocarcinoma

Figure 3. Kaplan–Meier overall survival for elderly patients with locally advanced squamous cell carcinoma (A) or adenocarcinoma (B) of the esophagus
stratified by type of treatment. *P value for only the comparison between esophagectomy alone and definitive concurrent chemoradiation in
squamous cell carcinoma patients was 0.44. All other comparisons were statistically significant.

treated at a nonacademic cancer center (OR 3.9) were
more likely to receive esophagectomy alone (Table 4).
After propensity matching (697 patient pairs), there was
a significant improvement in median survival from

© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

15.3 months (95% CI: 13.3–17.3) in the concurrent chemoradiation group to 19.8 months (95% CI: 16.5–23.2) among
esophagectomy alone patients, P < 0.001 (Figs. S6 and
S7).
2891
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Table 3. Multivariate analyses of predictors of treatment utilization for definitive and palliative therapy in elderly patients with locally advanced
esophageal cancer.
Variable

Palliative

Definitive

Palliative therapy versus no treatment

Trimodality therapy versus concurrent chemoradiation

Odds ratio
Age ≥80 (Ref: 70–79)
0.73
Female gender
0.81
High-volume center (Ref:
0.83
low-volume)
Tumor location (Ref: lower third)
Cervical
1.45
Upper third
1.13
Lower third
1.01
Unknown
0.79
Education level: <21%
1.25
with no high school
diploma (Ref: ≥21%)
Insurance status (Ref: uninsured)
Private
1.55
Medicaid
1.52
Medicare
1.77
Other government
3.79
Charlson-Deyo score (Ref: 0)
1
0.85
≥2
0.82
Clinical stage III (Ref: stage II)
0.80
Non-Caucasian race (Ref:
Caucasian)
Income ≥$38,000 (Ref:
<$38,000)
Adenocarcinoma histology
(Ref: squamous)

95% CI

P value

Odds ratio

95% CI

P value

0.65–0.81
0.72–0.91
0.73–0.95

<0.001
<0.001
0.008

0.15
0.80
2.34

0.12–0.18
0.69–0.92
2.07–2.65

<0.001
0.03
<0.001

1.05–2.00
0.90–1.41
0.86–1.18
0.68–0.91
1.08–1.45

0.02
0.03
0.90
0.001
0.003

N/A
2.76
4.09
2.41

1.82–4.19
2.74–6.11
1.59–3.67

<0.001
<0.001
<0.001

0.87–2.76
0.73–3.14
1.01–3.09
1.63–8.81

0.14
0.26
0.045
0.002

0.74–0.97
0.67–0.99
0.72–0.90

0.015
0.04
<0.001
0.63

0.48 to 0.81

<0.001

1.21

1.03–1.42

0.02

2.10

1.80–2.45

<0.001

Predictors of outcome
Risk factors for survival in the full elderly cohort were
analyzed using a Cox proportional hazards model (Table 5).
Increased overall mortality was associated with age ≥80
(HR 1.21), a Charlson-
Deyo comorbidity score ≥1 (HR
1.21–1.41), and clinical stage III (HR 1.31, reference: stage
II). Decreased mortality hazard was associated with female
gender (HR 0.94), higher income (HR 0.93), receiving care
at a high-volume center (HR 0.83), and adenocarcinoma
histology (HR 0.94). Any tumor-directed therapy resulted
in an independent relative improvement in survival over
no treatment with more substantial mortality hazard reduction being achieved for each therapy type: palliative therapy
(HR 0.49), definitive chemoradiation (HR 0.36), esophagectomy (HR 0.31), and trimodality (HR 0.25), respectively.
Since adenocarcinoma histology was associated with
improved survival and was a very strong predictor of
receiving trimodality therapy, we then explored outcomes
after definitive treatment based on histology. In the
unmatched cohort, median overall survival with trimodality
2892

therapy was 27.7 months (95% CI: 25.5–30.0) in patients
with adenocarcinoma and 24.8 months (95% CI: 19.7–30.0)
in patients with squamous cell carcinoma; however, this
difference was not statistically significant (P = 0.14, Figure
S8A). For those treated with concurrent chemoradiation,
median survivals of patients with adenocarcinoma and
squamous cell histology, while significantly different, were
days apart at 14.1 and 14.3 months, respectively (P < 0.001)
(Table S5, Figure S8B).

Discussion
Among a modern cohort of elderly patients with locally
advanced esophageal cancer, our results demonstrate significant variability in treatment utilization and associated
outcomes based on demographic and tumor characteristics.
Treatment decisions were significantly influenced by age,
sex, and treatment center patient volume. Race, comorbidities, education, income, and tumor location and histology also impacted utilization in specific scenarios.

© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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Table 4. Multivariate analysis of predictors of esophagectomy alone
compared to definitive chemoradiation.
Variable

Odds ratio

Age ≥80 (Ref: 70–79)
0.79
Clinical stage III (Ref: stage II)
0.33
Charlson-Deyo score (Ref: 0)
1
1.31
≥2
1.47
Tumor location (Ref: lower third)
Upper third
0.31
Middle third
0.69
Adenocarcinoma histology
1.33
(Ref: squamous)
Nonacademic cancer center
3.9
(Ref: academic center)

95% CI

P value

0.65–0.96
0.27–0.40

0.015
<0.001

1.07–1.61
1.07–2.04

0.01
0.02

0.19–0.51
0.53–0.91
1.07–1.67

<0.01
0.008
0.012

3.2–4.6

<0.001

Table 5. Hazard ratios for death for elderly patients with locally advanced esophageal cancer
Variable

Hazard
ratio

95% CI

P value

Age ≥80 (Ref: 70–79)
Female Gender
Income ≥$38,000 (Ref: <$38,000)
Charlson-Deyo score (Ref: 0)
1
≥2
High-volume center
(Ref: low-volume)
Clinical stage III (Ref: stage II)
Adenocarcinoma histology
(Ref: squamous)
Treatment type (Ref: no treatment)
Palliative therapy
Concurrent chemoradiation
Esophagectomy alone
Trimodality therapy

1.21
0.94
0.93

1.15–1.27
0.90–0.98
0.88–0.98

<0.001
0.009
0.006

1.21
1.42
0.83

1.15–1.27
1.31–1.53
0.79–0.87

<0.001
<0.001
<0.001

1.31
0.94

1.26–1.37
0.90–0.98

<0.001
0.03

0.49
0.36
0.31
0.25

0.46–0.53
0.34–0.39
0.28–0.34
0.23–0.27

<0.001
<0.001
<0.001
<0.001

Tumor-directed therapy resulted in improved survival over
no therapy with incremental improvement as the aggressiveness of treatment increased from palliative therapy to
definitive chemoradiation to surgical management of
disease.
Within the elderly cohort, age was one of the strongest
predictors for treatment utilization and survival. Patients
≥80 years old were more likely to receive no treatment
in the nondefinitive setting and much less likely to receive
trimodality therapy and esophagectomy alone when treated
definitively. Underlying these differences is likely a combination of patient-
related factors, physician bias, and
clinical realities. Numerous studies across various malignancies have shown that advanced age is associated with
decreased referral to specialists, increased delivery of suboptimal therapy, and increased patient refusal of therapy
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[16–19]. Objective clinical reasons supporting a more
cautious approach to older individuals include decreased
stem-cell reserves and the presence of comorbidities impacting drug absorption and/or metabolism [20, 21].
Additionally, esophagectomy has been associated with
higher rates of perioperative mortality in the elderly [5].
Indeed, we observed a higher percentage of 30-and 90-
day mortality in the ≥80 age group, though the absolute
number of deaths is smaller than the 70–79-year-old group
and the rates in the ≥80 group may be overestimated
due to the relatively small number of patients in that
age group (~6% of the trimodality cohort). Nevertheless,
in appropriately selected individuals, morbidity and mortality from esophagectomy is comparable to younger
patients in other studies, even for octogenarians [22, 23].
As it relates to the impact on survival, our data support
the use of more aggressive therapy, including surgery, in
the elderly patient with locally advanced esophageal cancer.
While patient selection can impact these findings, we do
see consistent improvement in outcomes with more aggressive therapy in matched cohorts as well.
Gender was also a predictor of treatment utilization and
survival with women appearing to be treated less aggressively. The presence and causes of gender disparities in
cancer treatment are not well defined, in part because many
malignancies are gender-
specific. However, a SEER-
based
analysis on colorectal cancer patients found that women,
particularly octogenarians, underwent less aggressive therapy
than men [24]. Despite this, women in this study and in
our cohort had improved survival [24]. Factors underlying
this contradiction are not clear, especially since women in
our cohort were older (mean age 78.2 vs. 77, P < 0.001).
While a difference in death from intercurrent disease is
likely a contributor, gender differences in disease progression and treatment response are an underexplored possibility.
Our results argue that care should be taken not to avoid
aggressive therapy in elderly females with locally advanced
esophageal cancer as their survival is comparable if not
improved from their male counterparts.
In our elderly cohort, a significant percentage (37.2%)
is not given definitive therapy for locally advanced disease.
Of these patients, we see a near threefold improvement
in median survival with palliative treatment compared to
no therapy. The benefit of a particular palliative strategy
is difficult to ascertain due to the heterogeneity of treatment approaches, but a large majority (~85%) received
radiation therapy and nearly half received chemotherapy.
Additionally, the improved survival with palliative therapy
can be impacted by patient selection factors not well
appreciated in the NCDB (e.g., performance status) or
by including patients not expressly coded as palliative
and thus potentially being treated more aggressively in a
definitive-type manner. Nevertheless, any nonconcurrent
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chemoradiation strategy is in practice a palliative therapy
for locally advanced disease. And while the true benefit
of palliative therapy is unclear, our data suggest that
tumor-directed therapy, even potentially with modest treatment such as radiation alone can have a significant impact
on survival. Importantly, the impact of these therapies
on quality of life is not well characterized and should
continue to be an important variable in deciding whether
or not to offer palliative treatment.
In the definitive setting, there has been a shift away
from upfront esophagectomy to trimodality with neoadjuvant chemoradiation, particularly after the CROSS trial
demonstrated improved outcomes over surgery alone [7].
While patients over 75 years old were excluded in this
study, this trend is nonetheless mirrored in our elderly
cohort where we see increased utilization of trimodality
from 2006 (6.7% of treatments) compared to 2012 (13.6%).
In this regard, our cohort is more aligned with current
practice than previous population-based analyses of elderly
patients where only 7% received trimodality [15, 16]. Of
note, the CROSS trial demonstrated a wider differential
in median survival between trimodality and esophagectomy
alone compared to our cohort (49 months vs. 24 months
in the CROSS trial compared to 27 months vs. 19 months).
This is most likely primarily due to the (intended) advanced
age of our cohort with a 17-year increase in median age
(60 vs. 77) and the increased likelihood of competing risks
as a result, though trimodality still appears to be associated with an improved survival in these elderly patients.
Nevertheless, a small percentage of patients (5.6%) were
treated with esophagectomy alone, and this may be due
to a preference for surgical management of locally advanced
disease as an alternative to chemoradiation in patients who
are not felt to be appropriate candidates for trimodality
therapy. Among our entire cohort, patients treated with
esophagectomy alone did exhibit improved overall survival
over chemoradiation, though this benefit may be more
apparent in those with adenocarcinoma specifically.
Among patients receiving trimodality, we see a strong
histologic bias toward adenocarcinomas. While adenocarcinoma histology was also associated with improved survival, there was no difference in survival between histologies
within the trimodality group. The improved hazards ratio
for adenocarcinoma, therefore, is likely the results of
increased (threefold) utilization of a more effective treatment. Nevertheless, factors underlying this bias toward
adenocarcinoma for trimodality are unclear. One possibility
is the differences in tumor location and associated differences in surgical approaches and complexities, and this
may explain the bias toward adenocarcinoma in patients
receiving esophagectomy alone as well. Squamous cell
carcinomas are more often in the mid and proximal
esophagus where surgery is more extensive or significantly
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morbid [25]. Other possibilities include the epidemiologic
differences between the two histologies and the growing
evidence that in squamous cell carcinoma, definitive
chemoradiation can result is comparable survival to treatments involving surgery [26–28]. Indeed, when we evaluated overall survival in the full cohort by histology and
examined squamous cell carcinoma specifically, esophagectomy alone appears to offer no significant survival advantage
over definitive chemoradiation.
Limitations of our study include the inability to reliably account for important factors such as comorbidities
and performance status. This limits our ability to account
for important patient selection criteria in treatment utilization, and can have a subsequent impact on survival
analysis, though we attempted to mitigate this effect
through propensity matching. Additionally, quality of life
outcomes are an important determinant in this population, but are unable to be garnered from the NCDB.
Finally, in the elderly when there is more likelihood of
competing comorbidities, the inability to ascertain disease
or progression-free survival is a further limitation when
evaluating the benefit of therapy. This effect is somewhat
offset by the aggressiveness of locally advanced esophageal
cancer (median survival of 2.2 years with trimodality)
relative to the average life expectancy in this age group
(4–17 years) [29].
In conclusion, our analysis of the NCDB demonstrates
that elderly patients with clinical stage II and III esophageal cancer exhibited a survival benefit from any tumor-
directed therapy, including palliative treatment. The use
of trimodality confers the largest survival benefit and
its use has increased over time. Despite these improved
outcomes with treatment, there are still numerous factors including age, gender, and histology as well as treatment at high-or low-volume centers that significantly
impact treatment utilization and care should be taken
to avoid bias in determining the most appropriate therapy
for the elderly patient with locally advanced esophageal
cancer.
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Supporting Information
Additional supporting information may be found in the
online version of this article:
Figure S1. Relative utilization of each treatment over
time. For each treatment group, the percentage of patients
in that group is plotted by year of diagnosis as a function
of all patients receiving that treatment. Percentages generally increase over time as patient numbers increase, with
the relative use of trimodality outpacing other treatment.
Figure S2. Kaplan–Meier overall survival from propensity-
matched elderly patients with locally advanced esophageal
cancer receiving palliative therapy or no treatment.
Figure S3. Dot-plot (A) and propensity histograms (B)
for propensity-
matched elderly patients with locally
advanced esophageal cancer receiving palliative therapy
or no treatment.
Figure S4. Kaplan–Meier overall survival from
propensity-matched elderly patients with locally advanced
esophageal cancer receiving concurrent chemoradiation or
trimodality therapy.
Figure S5. Dot-plot (A) and propensity histograms (B)
for propensity-
matched elderly patients with locally
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advanced esophageal cancer receiving concurrent chemoradiation or trimodality therapy.
Figure S6. Kaplan–Meier overall survival from
propensity-matched elderly patients with locally advanced
esophageal cancer receiving concurrent chemoradiation or
esophagectomy alone.
Figure S7. Dot-plot (A) and propensity histograms (B)
for propensity-
matched elderly patients with locally
advanced esophageal cancer concurrent chemoradiation
or esophagectomy alone.
Figure S8. Kaplan–Meier overall survival of elderly
patients with locally advanced esophageal cancer receiving
concurrent chemoradiation or trimodality by histology.
Table S1. Univariate analysis of predictors of palliative
therapy. Within each variable, patients with unknown
values were excluded and the number of remaining patients
(n) was noted within each variable and treatment group
when applicable.
Table S2. Univariate analysis of predictors of trimodality
therapy. Within each variable, patients with unknown
values were excluded and the number of remaining patients
(n) was noted within each variable and treatment group
when applicable.
Table S3. Perioperative outcomes in patients undergoing
trimodality therapy by age group.
Table S4. Univariate analysis of predictors of esophagectomy alone. Within each variable, patients with unknown
values were excluded and the number of remaining patients
(n) was noted within each variable and treatment group
when applicable.
Table S5. Survival after definitive therapy based on
tumor histology.
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